According to the Tourette Association of America, several trials have reported a reduction in tics with medical marijuana. Credit: GoodIdeas / Shutterstock.

SciSparc has received approval from the institutional review board (IRB) of Yale University School of Medicine in the US to commence Phase IIb trials for SCI-110 in Tourette syndrome.

The Phase IIa trial for SCI-110 was also previously conducted at Yale.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Other sites for the randomised, multi-centre, placebo-controlled cross-over Phase IIb trial include the Hannover Medical School in Germany and the Tel Aviv Sourasky Medical Center in Israel.

Tourette syndrome is a neurological condition that causes a person to have ‘tics’, involuntary movements, and sounds. So far, there is no reported cure for the condition and according to the Centres for Disease Control and Prevention (CDC), only symptomatic treatment is accessible.

According to the Tourette Association of America, several trials have reported a reduction in tics with medical marijuana, synthetic tetrahydrocannabinol (THC). However, these have the potential for adverse effects.

SCI-110 contains Dronabinol, a synthetic THC, in combination with endocannabinoid palmitoylethanolamide (PEA) to augment Dronabinol’s effect. This can, in turn, reduce Dronabinol’s dosage and adverse effects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary objective of the Phase IIb trial is a decrease in the severity of ‘tics’, assessed at 12 and 26 weeks using the Yale Global Tic Severity Scale (YGTSS-R-TTS). The absolute and relative number of adverse events will also be assessed.

Emalex Biosciences reported positive Phase IIb data for the use of ecopipam in Tourette syndrome in January 2023 while Immune globulin (human) by Octapharma for Tourette’s is currently in Phase III clinical trials.